Financial Risk

Neovest fine stokes the EMS transaction fee debate

The SEC’s fine for J.P. Morgan’s Neovest could signal a shift in how the industry views contentious EMS transaction fees. Chartis’ research shows that, as regulatory pressure mounts, investment managers and vendors may have to rethink their transaction…

You need to sign in to use this feature. If you don’t have a RiskTech Forum account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here: